Amylin Receptor Agonists

Compounds that stimulate the activity of AMYMIN RECEPTORS. Included under this heading is the endogenous form of ISLET AMYLOID POLYPEPTIDE and synthetic compounds that mimic its effect.

Also Known As:

Amylin Agonists; Amylin Mimetics; Amylin Receptor Agonist; Agonist, Amylin Receptor; Agonists, Amylin; Agonists, Amylin Receptor; Mimetics, Amylin; Receptor Agonist, Amylin; Receptor Agonists, Amylin

Networked: 20 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Amylin Receptor Agonists: 20
  - Physiological Effects of Drugs: 1
    - Hypoglycemic Agents: 14973
      - Amylin Receptor Agonists: 20

Experts

1.	Le Foll, Christelle: 2 articles (04/2021 - 01/2018)
2.	Lutz, Thomas A: 2 articles (04/2021 - 07/2015)
3.	Jerlhag, Elisabet: 2 articles (01/2021 - 01/2019)
4.	Kalafateli, Aimilia Lydia: 2 articles (01/2021 - 01/2019)
5.	Hay, Debbie L: 2 articles (09/2018 - 07/2015)
6.	Hansen, Henrik H: 1 article (04/2021)
7.	Hecksher-Sørensen, Jacob: 1 article (04/2021)
8.	Jelsing, Jacob: 1 article (04/2021)
9.	Roostalu, Urmas: 1 article (04/2021)
10.	Salinas, Casper G: 1 article (04/2021)

Related Diseases

1.	Weight Loss (Weight Reduction) 01/01/2018 - "Several other studies in obesity have shown that amylin agonists could also be useful for weight loss, especially in combination with other agents. " 07/01/2015 - "Clinical studies in obesity have shown that amylin agonists could also be useful for weight loss, especially in combination with other agents. " 12/01/2022 - "Cagrilintide is a novel long-acting amylin receptor agonist, which has shown a potent induction of weight loss. " 04/01/2011 - "Metformin and the dipeptidyl-peptidase-4 inhibitors were generally considered weight neutral, whereas the glucagon-like peptide-1 receptor agonists and amylin agonists were associated with weight loss. " 05/01/2010 - "The dipeptidyl peptidase-4 inhibitors are weight neutral, while the biguanides, incretin mimetics, and amylin mimetics promote weight loss. "
2.	Obesity 01/01/2018 - "Several other studies in obesity have shown that amylin agonists could also be useful for weight loss, especially in combination with other agents. " 07/01/2015 - "Clinical studies in obesity have shown that amylin agonists could also be useful for weight loss, especially in combination with other agents. " 09/14/2018 - "The data offer new insights into the function of peptide amidation, how allostery drives peptide-receptor interactions, and provide a valuable resource for the development of novel amylin agonists for treating diabetes and obesity." 06/01/2018 - "This review focuses on anti-obesity drugs in the pipeline including centrally acting agents (setmelanotide, neuropeptide Y antagonist [velneperit], zonisamide-bupropion [Empatic], cannabinoid type-1 receptor blockers), gut hormones and incretin targets (new glucagon-like-peptide-1 [GLP-1] analogues [semaglutide and oral equivalents], amylin mimetics [davalintide, dual amylin and calcitonin receptor agonists], dual action GLP-1/glucagon receptor agonists [oxyntomodulin], triple agonists [tri-agonist 1706], peptide YY, leptin analogues [combination pramlintide-metreleptin]), and other novel targets (methionine aminopeptidase 2 inhibitor [beloranib], lipase inhibitor [cetilistat], triple monoamine reuptake inhibitor [tesofensine], fibroblast growth factor 21), including anti-obesity vaccines (ghrelin, somatostatin, adenovirus36). "
3.	Metabolic Diseases (Metabolic Disease) 07/01/2012 - "Recently developed GLP-1 agonists and amylin agonists are examples of the therapeutic potential of such agents for metabolic diseases. " 04/27/2021 - "The pancreatic hormone amylin plays a central role in regulating energy homeostasis and glycaemic control by stimulating satiation and reducing food reward, making amylin receptor agonists attractive for the treatment of metabolic diseases. "
4.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/01/1997 - "Amylin agonists such as pramlintide may, therefore, be of value in improving glycaemic control in IDDM by modifying gastric emptying." 11/01/1994 - "There is little, if any, indication that either replacement of amylin or treatment with amylin agonists are likely to have any beneficial role in patients with IDDM."
5.	Diabetes Mellitus 09/01/2001 - "Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus." 01/01/2012 - "This article is a brief review of the current non-insulin agents for diabetes mellitus in the United States, namely, sulfonylureas, biguanides, thiazolidinediones, meglitinides, α-glucosidase inhibitors, glucacon-like peptide-1 receptor agonists, dipeptidyl-peptidase-4 inhibitors, amylin agonists, bromocriptine, and colesevelam. "

Related Drugs and Biologics

1.	Islet Amyloid Polypeptide
2.	Insulin (Novolin)
3.	Glucagon-Like Peptide 1 (GLP 1)
4.	Glucosidases
5.	Biguanides
6.	Glucagon-Like Peptide-1 Receptor Agonists
7.	pramlintide (Symlin)
8.	Incretins
9.	Thiazolidinediones
10.	Calcitonin Receptors (Calcitonin Receptor)

Related Therapies and Procedures

1.	Therapeutics